Eywa Pharma Manufacturing Facility Is Acquired By Biocon
Eywa Pharma Manufacturing Facility Is Acquired By Biocon: The oral solid dosage manufacturing facility of Eywa Pharma Inc., located in Cranbury, New Jersey, United States, has been acquired by Biocon Limited, an innovation-driven global biopharmaceutical company, it was announced on Friday through an exchange filing. The acquisition will take effect on 1 September 2023.
The facility was purchased for a total of $7.7 million USD. The facility’s current staff will shift to Biocon Generics Inc. as part of the transaction. The plant has the capacity to increase to 2 billion tablets/capsules annually.
“Obtaining ownership of this US FDA-approved facility, our first in the US, will complement Biocon’s existing production capabilities and strengthen our foothold in the US,” said Siddharth Mittal, Managing Director and CEO of Biocon Limited.
Pead This Also : Latest Business And Finance Updates
Through the diversification of our production infrastructure, purchasing will also enable us to add orally solid dosage capabilities for fresh products earlier than we had initially anticipated. We’ll concentrate on quickly integrating the new building and growing our clientele in the area.